Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
MACROGENICS INC amended First Amendment to the Purchase and Sale Agreement with Sagard Healthcare Partners valued at $60.0 million additional cash payment, aggregate purchase price $130.0 million (effective 2026-05-01).
- Action
- amendment
- Agreement
- asset purchase
- Counterparty
- Sagard Healthcare Partners
- Value
- $60.0 million additional cash payment, aggregate purchase price $130.0 million
- Effective
- 2026-05-01
Exact text from the filing
On May 1, 2026, MacroGenics, Inc. (the “Company”) and an entity affiliated with Sagard Healthcare Partners (“Sagard”) entered into a First Amendment (the “First Amendment”) to the Purchase and Sale Agreement, dated as of June 9, 2025 (the “Royalty Purchase Agreement”), pursuant to which the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) under the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agreement”), with Incyte Corporation.
View on SEC.gov